Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 Nov 29;: Authors: Bond DA, Dotson E, Awan FT, Baiocchi RA, Blum KA, Maddocks K PMID: 30594446 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Related Links:

In this study, around 20% of all patients with HBV reactivation developed HBV reactivation after 2 years from the initiation of therapy, unlike malignant lymphoma. This might be due to the fact that almost all of the patients received chemotherapy for a long duration. Therefore, a new strategy for the prevention of HBV reactivation in MM patients is required.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-...
Source: Journal of Leukocyte Biology - Category: Hematology Authors: Tags: J Leukoc Biol Source Type: research
Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, Andrea Lee, Joel Michalski, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj BhattAbstractBackgroundThe role of obesity in prognosis of acute myeloid leukemia(AML) is debatable. Our retrospective study aimed to determine the effect of obesity on overall survival(OS) in AML.MethodsAML patients diagnosed at University of Nebraska Medical Center were divided into 3-groups based on body mass index (BMI): normal(18.5-25kg/m2) or underweight(
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 7 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kaoru Morita, Masahiro Ashizawa, Yumiko Toda, Takashi Ikeda, Shin-ichiro Kawaguchi, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Chihiro Yamamoto, Kaoru Hatano, Shin-ichiro Fujiwara, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo MuroiAbstractAbout 40% of patients with diffuse large B cell lymphoma (DLBCL) relapse after or are refractory to standard chemotherapy with rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We aimed to determine the effect of obesity on overall survival(OS) in acute myeloid leukemia(AML). Total 314 patients were included in the study; 38% were obese. Actual body weight was used to dose chemotherapy in 92% of obese patients. On a multivariate analysis, obesity, compared to normal weight, conferred worse OS. OS was similar in obese and over-weight patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Kim De Veirman AXL belongs to the TAM (TYRO3, AXL, and MERTK) receptor family, a unique subfamily of the receptor tyrosine kinases. Their common ligand is growth arrest-specific protein 6 (GAS6). The GAS6/TAM signaling pathway regulates many important cell processes and plays an essential role in immunity, hemostasis, and erythropoiesis. In cancer, AXL overexpression and activation has been associated with cell proliferation, chemotherapy resistance, tumor angiogenesis, invasion, and metastasis; and has been correlated with a poor prognosis. In hematological malignancies, the expression and function of AXL is highly...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionThalidomide-based regimens are potential salvage treatment options for patients with RRMM, even with prior resistance to IMiDs.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: All tested biosimilars demonstrated similar effectiveness and safety profiles in patients with hematological tumors undergoing PBSC mobilization; therefore, they can be used interchangeably. PMID: 31663634 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Clin Apher Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Luo Huang, Yongzhong Wu, Ying Wang, Yue Xie, Furong Wu, Shujie Li, Zhongguo Liang, Xiaodong ZhuAbstractThe aim of this study is to develop a prognostic nomogram for early stage extranodal NK/T-cell lymphoma, nasal-type (ENKL) treated with high-dose radiotherapy (RT). A total of 81 patients at two cancer centers with stage I to IIE ENKL who received chemotherapy (CT) and high-dose RT were retrospectively analyzed. The 5-year OS rate and PFS were 64.7% and 57.5% respectively for the entire group. The development of the ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur findings indicate that prognostic testing rates were poor, and approximately one-third of high-risk patients (del[17p] and TP53) received chemoimmunotherapy, which is not aligned with current CLL treatment recommendations. This represents an opportunity to educate and alert healthcare professionals about the necessity of prognostic testing to guide optimal CLL treatment decisions. Study registration: NCT02582879 (ClinicalTrials.gov).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Lymphoma | Myeloma